Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neural...( NEW YORK April 6 /- Crystal Research ...)

NEW YORK, April 6 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. (NYSE Amex: CUR). The full 56-page report can be found at www.crystalra.com.

Neuralstem, Inc. ("Neuralstem" or "the Company") is a biotherapeutics company using a patented process to grow neural stem cells to treat central nervous system (CNS) diseases. The neurodegenerative conditions that the Company targets are incurable and are usually associated with severe side effects, such as muscle atrophy, partial or complete paralysis, or death. Neuralstem's proprietary Human Neural Stem Cell technology isolates stem cells from CNS tissue of the developing human brain and spinal cord and expands these cells in the laboratory for up to 60 doublings. By amplifying the natural ability of fetal stem cells to self-renew for long time periods, the Company creates billions of cells from each original stem cell--enabling commercial quantities from a sole donated tissue. To Neuralstem's knowledge, its technology was the first to accomplish both commercial quantities and controlled differentiation of neural stem cells into mature, physiologically relevant neurons and glia.

The initial product candidate of this therapeutic platform is a spinal cord cell line. When implanted into animal models, the cells have extended the lives of rats with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and reversed paralysis in ischemic spastic paraplegia models. In December 2008, Neuralstem filed an Investigational New Drug (IND) application for a Phase I trial of its spinal cord cells in patients with ALS, which affects roughly 30,000 people in the U.S. In February 2009, the Company received the FDA's response, which Neural
'/>"/>